Nicox Completes Key Data Generation for NCX 470 Glaucoma Drug, NDA Submission Planned for H1 2026
核心洞察
Nicox has successfully completed generation and analysis of all clinical trial and long-term stability data required for New Drug Applications (NDAs) in the U.S. and China for NCX 470, a novel nitric oxide-donating bimatoprost eye drop for glaucoma treatment.
The company is preparing for a pre-NDA meeting with the FDA and remains on track to submit the U.S. NDA in the first half of 2026, with China submission expected shortly after.
NCX 470 represents a potential advancement in glaucoma therapy as a nitric oxide-donating formulation designed to lower intraocular pressure in patients with open-angle glaucoma (搜索) or ocular hypertension (搜索).
Nicox SA (搜索) has achieved a critical regulatory milestone by completing all key data generation required for New Drug Application (NDA) submissions of NCX 470, its novel nitric oxide-donating bimatoprost eye drop for glaucoma treatment. The French ophthalmology company announced December 16 that it has successfully generated and analyzed all clinical trial and long-term stability data needed to support NDA submissions in both the United States and China.
Regulatory Data Package Complete
The completed data package includes all clinical trial results and long-term stability data compliant with International Council for Harmonisation (ICH) guidelines for both the NCX 470 drug material and finished drug product. These elements provide evidence to support manufacturing processes, shelf-life specifications, and drug metabolism profiles - standard requirements for NDA submissions.
"We have achieved this milestone through close collaboration of our committed and dedicated team with our clinical and manufacturing partners and specialist research organisations," said Doug Hubatsch, EVP and Chief Scientific Officer of Nicox. "It marks a major step towards generating long-term value from NCX 470 and positioning Nicox for the future."
Regulatory Timeline and Partnership Structure
Nicox is now proceeding with NDA preparation, which is being conducted at the cost of Kowa, the company's licensing partner for the U.S. market. The development team is focusing on supporting Kowa's preparation for an upcoming pre-NDA meeting with the Food and Drug Administration.
The U.S. NDA submission remains on track for the first half of 2026, with the China NDA submission expected shortly thereafter. Additionally, a Phase 3 clinical program in Japan was initiated in summer 2025, managed and financed by Kowa.
NCX 470 Development Program
NCX 470 (bimatoprost grenod) represents a novel approach to glaucoma treatment as a nitric oxide-donating bimatoprost formulation designed to lower intraocular pressure in patients with open-angle glaucoma (搜索) or ocular hypertension (搜索). The drug is licensed to Ocumension Therapeutics (搜索) for Chinese, Korean and Southeast Asian markets, while Kowa holds licensing rights for the rest of the world.
The completion of this regulatory data package positions NCX 470 as Nicox's lead late-stage development program, building on the company's established presence in ophthalmology through its existing commercial products including VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.